BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23454533)

  • 1. Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy.
    Vera G; Cabezos PA; Martín MI; Abalo R
    Pharmacol Biochem Behav; 2013 Apr; 105():205-12. PubMed ID: 23454533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes.
    Vera G; López-Miranda V; Herradón E; Martín MI; Abalo R
    Pharmacol Biochem Behav; 2012 Aug; 102(2):335-43. PubMed ID: 22609797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
    Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
    Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis.
    Gutierrez T; Farthing JN; Zvonok AM; Makriyannis A; Hohmann AG
    Br J Pharmacol; 2007 Jan; 150(2):153-63. PubMed ID: 17160008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain.
    Toth CC; Jedrzejewski NM; Ellis CL; Frey WH
    Mol Pain; 2010 Mar; 6():16. PubMed ID: 20236533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L; Cornett BL; Mackie K; Hohmann AG
    Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal cannabinoid CB1 or CB2 receptors activation attenuates mechanical allodynia in streptozotocin-induced diabetic rats.
    Gonçalves MR; da Conceição MS; Jesus CHA; Gasparin AT; Rosa ES; da Cunha JM
    Behav Pharmacol; 2022 Apr; 33(2&3):158-164. PubMed ID: 32804775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptors 1 and 2 are associated with bladder dysfunction in an experimental diabetic rat model.
    Li Y; Sun Y; Zhang Z; Feng X; Meng H; Li S; Zhu Y; Chen S; Wang Y; Wang J; Zhang D; Jiang X; Li N; Shi B
    BJU Int; 2013 Jul; 112(2):E143-50. PubMed ID: 23795792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.
    Mulpuri Y; Marty VN; Munier JJ; Mackie K; Schmidt BL; Seltzman HH; Spigelman I
    Neuropharmacology; 2018 Sep; 139():85-97. PubMed ID: 29981335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
    Bagüés A; Martín MI; Sánchez-Robles EM
    Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat.
    Vera G; López-Gómez L; Girón R; Martín-Fontelles MI; Nurgali K; Abalo R; Uranga JA
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.
    Pascual D; Goicoechea C; Suardíaz M; Martín MI
    Pain; 2005 Nov; 118(1-2):23-34. PubMed ID: 16213089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Se-phenyl thiazolidine-4-carboselenoate on mechanical and thermal hyperalgesia in brachial plexus avulsion in mice: mediation by cannabinoid CB1 and CB2 receptors.
    Del Fabbro L; Borges Filho C; Cattelan Souza L; Savegnago L; Alves D; Henrique Schneider P; de Salles HD; Jesse CR
    Brain Res; 2012 Sep; 1475():31-6. PubMed ID: 22902772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
    Brownjohn PW; Ashton JC
    Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic cannabinoids produce CB₁-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT(7) and 5-HT(2A) receptors.
    Seyrek M; Kahraman S; Deveci MS; Yesilyurt O; Dogrul A
    Eur J Pharmacol; 2010 Dec; 649(1-3):183-94. PubMed ID: 20868676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
    Sain NM; Liang A; Kane SA; Urban MO
    Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
    De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
    J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiallodynic effect of PhAR-DBH-Me involves cannabinoid and TRPV1 receptors.
    Quiñonez-Bastidas GN; Palomino-Hernández O; López-Ortíz M; Rocha-González HI; González-Anduaga GM; Regla I; Navarrete A
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00663. PubMed ID: 32965798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.